161 related articles for article (PubMed ID: 29605670)
1. Serum Soluble CD48 Levels as a Prognostic Marker in Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T; Takahashi N; Nakajima R; Kamijo H; Suga H; Asano Y; Sugaya M; Sato S
J Invest Dermatol; 2018 Oct; 138(10):2286-2288. PubMed ID: 29605670
[No Abstract] [Full Text] [Related]
2. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
3. Increased serum neopterin levels in mycosis fungoides and Sézary syndrome.
Hamerlinck FF; Toonstra J; van Vloten WA
Br J Dermatol; 1999 Dec; 141(6):1136-7. PubMed ID: 10722267
[No Abstract] [Full Text] [Related]
4. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma.
Ohmatsu H; Sugaya M; Suga H; Morimura S; Miyagaki T; Kai H; Kagami S; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2012 May; 92(3):282-3. PubMed ID: 22456907
[No Abstract] [Full Text] [Related]
5. Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides.
Hurabielle C; Michel L; Ram-Wolff C; Battistella M; Jean-Louis F; Beylot-Barry M; d'Incan M; Bensussan A; Bagot M
J Invest Dermatol; 2016 Jan; 136(1):317-20. PubMed ID: 26763453
[No Abstract] [Full Text] [Related]
6. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and Helios Are Highly Expressed on CD4
Jariwala N; Benoit B; Kossenkov AV; Oetjen LK; Whelan TM; Cornejo CM; Takeshita J; Kim BS; Showe LC; Wysocka M; Rook AH
J Invest Dermatol; 2017 Jan; 137(1):257-260. PubMed ID: 27592800
[No Abstract] [Full Text] [Related]
8. Report of the Committee on Pathology of Cutaneous T Cell Lymphomas.
Clendenning WE; Rappaport HW
Cancer Treat Rep; 1979 Apr; 63(4):719-24. PubMed ID: 376141
[No Abstract] [Full Text] [Related]
9. Increased Serum Activin A Levels in Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T; Kamijo H; Nakajima R; Shishido-Takahashi N; Senda N; Suga H; Sugaya M; Sato S
Acta Derm Venereol; 2019 Oct; 99(11):1039-1040. PubMed ID: 31240323
[No Abstract] [Full Text] [Related]
10. Serum-soluble herpes virus entry mediator levels reflect disease severity and Th2 environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2013 Jul; 93(4):465-7. PubMed ID: 23306973
[No Abstract] [Full Text] [Related]
11. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
12. Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome.
Otobe S; Sugaya M; Nakajima R; Oka T; Takahashi N; Kabasawa M; Miyagaki T; Asano Y; Sato S
J Dermatol; 2018 Apr; 45(4):468-471. PubMed ID: 29314201
[TBL] [Abstract][Full Text] [Related]
13. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
15. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-15 levels are not elevated in patients with stage I and II mycosis fungoides.
Sugaya M; Nakamura K; Tamaki K
Acta Derm Venereol; 2000; 80(6):455. PubMed ID: 11243648
[No Abstract] [Full Text] [Related]
17. The Sézary cell in the blood of patients with mycosis fungoides.
Winkelmann RK; Hoagland HC
Dermatologica; 1980; 160(2):73-9. PubMed ID: 6965373
[TBL] [Abstract][Full Text] [Related]
18. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
19. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
20. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
